一分钟看懂
这是一项关于结直肠癌的II 期研究，登记的药物或干预包括TAS-102，当前状态为招募中。登记地点显示中国Houston有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
TAS-102 · II 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- MD Anderson Cancer Center · Houston
公开的入选条件
- 1. Has histological confirmation of colorectal cancer
- 2. Received post-R0 resection of stages II, III, or IV colorectal cancer and has completed all planned curative intent therapies that must include ≥ 3 months of oxaliplatin containing chemotherapy
- 3. Has no definitive evidence of radiographic disease per assessment by investigators within 28 days (before or after) a positive ctDNA assay
- 4. Has minimal residual disease as defined by positive ctDNA assay (completed as standard-of-care at MD Anderson). Patients may be identified for enrollment with any Clinical Laboratory Improvement Amendments (CLIA)-certified ctDNA assay for MRD. MRD status wi
- 5. Has adequate organ and marrow function as defined below:
- 1. absolute neutrophil count: ≥1,000/mcL
- 2. platelets: ≥100,000/mcL
- 3. total bilirubin: ≤ institutional upper limit of normal (ULN)
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT05343013；登记信息更新于 2026-09-16。